Vertex Pharmaceuticals has presented new data showing the clinical and quality-of-life benefits of its cystic fibrosis (CF) therapies, particularly Alyftrek (deutivacaftor/tezacaftor/vanzacaftor). The findings, shared at the 48th European Cystic Fibrosis Conference, 4 to 7 June 2025, Milan, Italy, highlight the potential of CF transmembrane conductance regulator (CFTR) modulators to significantly improve patient outcomes. A combined […]
The post Vertex presents promising new data from cystic fibrosis trials appeared first on Pharmafile.
